MedTrace Logo

A Study of Risperidone Monotherapy in Bipolar Anxiety

NCT00167479 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2006-09-11

No results posted yet for this study

Summary

The specific aim of this study is to evaluate the efficacy, tolerability, and safety of risperidone monotherapy in the treatment of ambulatory bipolar disorder with comorbid lifetime panic disorder or generalized anxiety disorder and current at least moderately severe anxiety.

Conditions

Interventions

DRUG

risperidone (Risperdal)

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • University of South Florida

    lead OTHER

Principal Investigators

  • David V. Sheehan, MD, MBA · University of South Florida College of Medicine

  • Susan L. McElroy, MD · University of Cincinatti, Department of Psychiatry

  • Trisha - Suppes, MD, PhD · University of Texas Southwestern Medical Center

  • Paul E. Keck, MD · University of Cincinatti, Department of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00167479 on ClinicalTrials.gov